CTOs on the Move

Envision Healthcare

www.envisionhealth.com

 
Envision Healthcare is on the front lines of change. Through our primary business units – Envision Physician Services, Evolution Health and AMSURG – our clinician-led organization is changing the face of healthcare by delivering high-quality care that elevates the patient experience. Envision Healthcare is pioneering solutions to the toughest challenges in healthcare. We serve as a partner to help navigate the constantly evolving landscape of healthcare delivery, and we are vigilant in working with health systems and hospitals to identify opportunities to better serve our communities. Our physicians, advanced practice providers and support teams are responsible for more than 30 ...
  • Number of Employees: 25-100
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Carrie Damon
 Chief Information Officer Profile
Nathan Roe
 Director of IT Internal Audit Profile
Robert Johnson
 Vice President - IT Governance and Integrations Profile
John Glasser
 Director, IT Project Planning and Financial Operations Profile

Similar Companies

Bonfils Blood Center

Bonfils Blood Center Foundation was established in 1995 as the fundraising arm of Bonfils Blood Center and serves the core function of encouraging and managing philanthropy to support a variety of programs and initiatives for Bonfils Blood Center. From

Buffalo Neurosurgery Group

Buffalo Neurosurgery Group is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Buffalo, NY. To find more information about Buffalo Neurosurgery Group, please visit www.buffaloneuro.com

American Dental

American Dental is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rome Health

Rome Health is a comprehensive healthcare system that delivers quality, compassionate medical care for every stage of life.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.